Local approaches to hereditary breast cancer

Annals of Oncology

Volumn 24, Issue SUPPL.B, 2013, Pages

  Cooper, B T ^a   Murphy, J O ^b   Sacchini, V ^b   Formenti, S C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BRCA1; BRCA2; Hereditary breast cancer; Radiation; Radiation induced malignancy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; TAMOXIFEN;

ANXIETY; ARTICLE; BREAST CANCER; BREAST EXAMINATION; BREAST SURGERY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ECHOMAMMOGRAPHY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FAMILIAL CANCER; GENE MUTATION; GENETIC SCREENING; HEREDITARY BREAST CANCER; HETEROZYGOTE; HUMAN; IONIZING RADIATION; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PLASTIC SURGERY; PRIORITY JOURNAL; RADIATION DOSE; RISK REDUCTION; SALPINGOOOPHORECTOMY; SELF EXAMINATION; SENSITIVITY AND SPECIFICITY; SURGICAL TECHNIQUE; TUMOR SUPPRESSOR GENE;

BRCA1; BRCA2; HEREDITARY BREAST CANCER; RADIATION; RADIATION-INDUCED MALIGNANCY;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MUTATION;

EID: 84886249511     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt327     Document Type: Article

References (62)

1. American Cancer Society, Cancer Facts & Figures 2012.http://www.cancer.org/ acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf (20 December 2012, date last accessed).
2. Ford D, Easton D, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
3. Newman B, Mu H, Butler LM et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998; 279: 915-921.
4. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
5. Chen S, Iverson ES, Friebel T et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006; 24: 863-871.
6. Warner E, Plewes DB, Hill KA et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292: 1317-1325.
7. Cuzick J, Forbes JF, Sestak I et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99: 272-282.
8. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652-1662.
9. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008; 122: 2017-2022.
10. Kauff ND, Domchek SM, Friebel TM et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26: 1331-1337.
11. Kaas R, Verhoef S, Wesseling J et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg 2010; 251: 488-492.
12. Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 1055-1062.
13. Liebens FP, Carly B, Pastijn A et al. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 2007; 43: 238-257.
14. Pierce LJ, Phillips KA, Griffith KA et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010; 121: 389-398.
15. Schwartz MD, Lerman C, Brogan B et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004; 22: 1823-1829.
16. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2012, Hereditary Breast and/or Ovarian Cancer Syndrome. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (20 December 2012).
17. Kuhl CK, Schrading S, Leutner CC et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23: 8469-8476.
18. Passaperuma K, Warner E, Causer PA et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 2012; 107: 24-30.
19. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines), Breast Cancer Screening and Diagnosis, Version 1.2012. http://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf (20 December 2012).
20. Ronckers CM, Erdmann CA, Land CE. Radiation and breast cancer: a review of current evidence. Breast Cancer Res 2005; 7: 21-32.
21. Nieuwenhuis B, Van Assen-Bolt AJ, Van Waarde-Verhagen MA et al. BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage. Int J Radiat Biol 2002; 78: 285-295.
22. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003; 22: 5784-5791.
23. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 2004; 95: 866-871.
24. Formenti SC, Preston-Martin S, Haffty BG. BRCA1/2 germline mutations: a marker for radioresistance or radiosensitivity? J Clin Oncol 2000; 18: 1159-1160.
25. Xia F, Powell S. The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer. Semin Radiat Oncol 2002; 12: 296-304.
26. Pijpe A, Andrieu N, Easton DF et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ 2012; 345: 1-15.
27. Satagopan JM, Boyd J, Kauff ND et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002; 8: 3777-3781.
28. Struewing JP, Hartge P, Wacholer S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408.
29. Finch A, Beiner M, Lubinski J et al. Salpingo-oophorectomy and the risk of ovarian, Fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006; 296: 185-192.
30. Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-1615.
31. Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-1622.
32. Kramer J, Velazquez IA, Chen BE et al. Prophylactic ooporectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 2005; 23: 8629-8653.
33. Domchek SM, Friebel TM, Singer CF et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 9: 967-975.
34. Rebbeck TR, Kauff ND, Domcheck SM. Meta-analysis of risk-reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA 2 mutation carriers. J Natl Cancer Inst 2009; 101: 80-87.
35. Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol 2007; 14: 3335-3344.
36. Julian-Reynier CM, Bouchard LJ, Evans DG et al. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 2001; 92: 959-968.
37. Botkin JR, Smith KR, Croyle RT et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 2003; 118A: 201-209.
38. Brandberg Y, Arver B, Lindblom A et al. Preoperative psychological reactions and quality of life among women with an increased risk of breast cancer who are considering a prophylactic mastectomy. Eur J Cancer 2004; 40: 365-374.
39. Patenaude AF, Orozco S, Li X et al. Support needs and acceptability of psychological and peer consultation: attitudes of 108 women who had undergone or were considering prophylactic mastectomy. Psychooncology 2008; 17: 831-843.
40. Lobb E, Meiser B. Genetic counselling and prophylactic surgery in women from families with hereditary breast or ovarian cancer. Lancet 2004; 363: 1841-1842.
41. Frost MH, Schnaid DJ, Sellers TA et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 2000; 284: 319-324.
42. Metcalfe KA, Esplen MJ, Goel V et al. Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. Psychooncology 2004; 13: 14-25.
43. Hopwood P, Lee A, Shenton A et al. Clinical follow-up after bilateral risk reducing ('prophylactic') mastectomy: mental health and body image outcomes. Psychooncology 2000; 9: 462-472.
44. Schwartz MD. Contralateral prophylactic mastectomy: efficacy, satisfaction, and regret. J Clin Oncol 2005; 23: 7777-7779.
45. Brandberg Y, Sandelin K, Erikson S et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 2008; 26: 3943-3949.
46. Frost MH, Slezak J, Tran NV et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 2005; 23: 7849-7856.
47. de Alcantara Filho P, Capko D, Barry JM et al. Nipple-sparing mastectomy for breast cancer and risk-reducing surgery: the Memorial Sloan-Kettering Cancer Center experience. Ann Surg Oncol 2011; 18: 3117-3122.
48. Euhus D. Managing the breast in patients who test positive for hereditary breast cancer. Ann Surg Oncol 2012; 19: 1738-1744.
49. King MC, Wieand S, Hale K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286: 2251-2256.
50. Rebbeck TR, Friebel T, Wagner T et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005; 23: 7804-7810.
51. Zhong Q, Chen CF, Li S et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 1999; 285: 747-750.
52. Kirova YM, Savignoni A, Sigal-Zafrani B et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat 2010; 120: 119-126.
53. Pierce LJ, Levin A, Rebbeck TR et al. Ten-year multi-institutional results of breastconserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006; 24: 2437-2443.
54. Robson M, Chappuis P, Satapogan J et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004; 6: R8-R17.
55. Robson M, Levin D, Federici J et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 1999; 91: 2112-2117.
56. Garcia-Etienne CA, Barile M, Gentilini OD et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol 2009; 16: 3380-3387.
57. Haffty BG, Harrold E, Knan AJ et al. Outcome of conservatively managed earlyonset breast cancer by BRCA1/2 status. Lancet 2002; 359: 1471-1477.
58. Metcalfe K, Lynch H, Ghadirian P et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004; 22: 2328-2335.
59. Metcalfe KA, Lubinski J, Ghadirian P et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008; 26: 1093-1097.
60. Van Sprundel TC, Schmidt MK, Rookus MA et al. Risk reduction and survival after contralateral prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2005; 93: 287-292.
61. Weitzel JN, McCaffrey SM, Nedelcu R et al. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 2003; 1323-1328.
62. The American Society of Breast Surgeons, Position Statement on BRCA Genetic Testing for Patients With and Without Breast Cancer, 30 September 2012. https://www.breastsurgeons.org/statements/PDF_Statements/BRCA_Testing.pdf (20 December 2012).